Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic

PT-141
PT-141
$53.00 Buy Now

PT-141

$53.00

Research-grade PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist (primarily MC4R) designed for controlled investigations of sexual arousal pathways, erectile function, libido modulation, and central melanocortin signaling.

Free shipping on all orders over $200 (US)

  • 99% Purity – Third-Party Tested
  • Fast & Reliable Shipping
Guaranteed Safe Checkout

PT-141 (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH) is a cyclic, lactam-bridged analog of α-melanocyte-stimulating hormone (α-MSH) originally developed by Palatin Technologies as a tanning peptide. Unlike PDE5 inhibitors (Viagra®), it acts centrally via melanocortin-4 receptor (MC4R) activation in the hypothalamus to trigger sexual arousal and desire in both males and females. FDA-approved in 2019 as Vyleesi® for hypoactive sexual desire disorder (HSDD) in premenopausal women, it remains the only clinically validated peptide for female sexual dysfunction. This research-grade lyophilized powder is synthesized under strict quality controls and provided with full analytical documentation.

Key Scientific

  • High-purity PT-141 (≥ 98% by HPLC/MS, acetate salt form)
  • Verified cyclic heptapeptide sequence with lactam bridge (Asp-Lys)
  • Lyophilized formulation for maximum long-term stability
  • Full Certificate of Analysis (COA) with HPLC, MS, and amino acid analysis
  • Manufactured in GMP-aligned, ISO-compliant facilities
  • Ideal for sexual behavior, MC4R signaling, and arousal pathway research

Research-Referenced Attributes (Based on scientific literature & clinical trials; not therapeutic claims.)

  • Central activation of MC4R → robust sexual arousal in both sexes (onset 30–90 min, duration 6–72 hours)
  • Phase 3 trials (RECONNECT): 1.75 mg subcutaneous → 25–35% increase in satisfying sexual eventsand FSFI desire score in women with HSDD
  • Male trials: spontaneous erections in 68–85% of doses vs. 19% placebo (p<0.01)
  • No significant blood pressure effects compared to earlier Melanotan-II
  • Potential applications in erectile dysfunction, female sexual arousal disorder, and obesity models
  • Nasal and subcutaneous bioavailability; crosses blood-brain barrier

Why Researchers Choose Nationwide Peptides PT-141

  • Exact clinical-sequence match to FDA-approved Bremelanotide (Vyleesi®)
  • Highest documented MC4R affinity among research suppliers
  • Transparent analytical data (HPLC >98%, MS confirmation of cyclic structure)
  • Trusted by neuroendocrinology, sexual medicine, and pharmacology laboratories
  • Competitive research pricing with bulk options

Storage & Handling

  • Store lyophilized powder at –4 °F (long-term) or 39.2 °F (short-term)
  • Protect from light, moisture, and air exposure
  • Reconstitute only with bacteriostatic water or sterile saline (typical concentration 5–10 mg/mL)
  • Reconstituted solutions stable at 39.2 °F for up to 4 weeks; avoid repeated freeze-thaw cycles
  • Use appropriate PPE and aseptic technique

Peptide Research